𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Comparative bioavailability and kinetics of folinic acid in the pharmaceutical formulations of Rescuvolin® and Ledervorin® in healthy volunteers

✍ Scribed by P. J. M. Guelen; T. B. Vree; D. De Vos; K. Lamers


Publisher
John Wiley and Sons
Year
1988
Tongue
English
Weight
363 KB
Volume
9
Category
Article
ISSN
0142-2782

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Bioavailability of pseudoephedrine from
✍ Vaishali Pade; Jagadeesh Aluri; Linda Manning; Salomon Stavchansky 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 498 KB 👁 2 views

A multiple-dose bioequivalence study with six healthy human volunteers was conducted. The bioavailability of an experimental controlled release tablet containing pseudoephedrine was compared with a marketed controlled release pseudoephedrine capsule in a three-way crossover study. Plasma samples, co

EFFECTS OF FOOD, ANTACID, AND DOSAGE FOR
✍ SHEKMAN L. WONG; PAUL LINNEN; RANDALL MACK; G. RICHARD GRANNEMAN 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB 👁 3 views

The pharmacokinetic disposition and relative bioavailability of sertindole administered as a tablet dosage form under fasting conditions, in the presence of food, in the presence of antacid, and as solution was studied in a four-way crossover in young healthy male volunteers. Overall, tablet dosing

Comparison of the bioavailability of 250
✍ Sandeep Dutta; Yiming Zhang; Lillian L. Lee; Robert O'Dea 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB 👁 1 views

Divalproex sodium extended-release tablet (divalproex-ER), 500 mg strength, is approved for use in the prophylaxis of migraine headaches and epilepsy. The bioavailability of novel 250 mg divalproex-ER formulations, under development to allow greater flexibility in dosing, was compared with the avail

Bioavailability of dextromethorphan (as
✍ S. Demirbas; L. Reyderman; S. Stavchansky 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 144 KB 👁 2 views

A multiple dose bioavailability study with six healthy male human volunteers was conducted. The bioavailability of an experimental sustained release tablet containing dextromethorphan hydrobromide (DXP-HBr), was compared with a marketed sustained release DXP-HBr suspension in a three-way crossover s